Cargando…

Ulipristal acetate as a treatment option for uterine fibroids

Uterine fibroids are the most common benign uterine tumours. Clinical symptoms include abnormal bleeding, pelvic pressure, pelvic pain, infertility and obstetric complications. Approximately one third of women with fibroids will require treatment. The management also depends on the number, size, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Piecak, Karolina, Milart, Paweł, Woźniakowska, Ewa, Paszkowski, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824685/
https://www.ncbi.nlm.nih.gov/pubmed/29483856
http://dx.doi.org/10.5114/pm.2017.72792
_version_ 1783302068295958528
author Piecak, Karolina
Milart, Paweł
Woźniakowska, Ewa
Paszkowski, Tomasz
author_facet Piecak, Karolina
Milart, Paweł
Woźniakowska, Ewa
Paszkowski, Tomasz
author_sort Piecak, Karolina
collection PubMed
description Uterine fibroids are the most common benign uterine tumours. Clinical symptoms include abnormal bleeding, pelvic pressure, pelvic pain, infertility and obstetric complications. Approximately one third of women with fibroids will require treatment. The management also depends on the number, size, and location of the fibroids. There are surgical and non-surgical treatment options. The choice of therapy depends on different factors, such as the severity of symptoms, tumour characteristics, age, and wish to preserve the uterus and fertility. There is growing evidence of the main role of progesterone pathways in the pathophysiology of uterine fibroids due to the use of selective progesterone receptor modulators such as ulipristal acetate. The efficacy of long-term intermittent use of UPA was recently demonstrated by randomised controlled studies. There is great demand for alternatives to surgical intervention, especially in women seeking to preserve their fertility. One of these alternatives is ulipristal acetate, which is proven to treat fibroid symptoms effectively.
format Online
Article
Text
id pubmed-5824685
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-58246852018-02-26 Ulipristal acetate as a treatment option for uterine fibroids Piecak, Karolina Milart, Paweł Woźniakowska, Ewa Paszkowski, Tomasz Prz Menopauzalny Review Paper Uterine fibroids are the most common benign uterine tumours. Clinical symptoms include abnormal bleeding, pelvic pressure, pelvic pain, infertility and obstetric complications. Approximately one third of women with fibroids will require treatment. The management also depends on the number, size, and location of the fibroids. There are surgical and non-surgical treatment options. The choice of therapy depends on different factors, such as the severity of symptoms, tumour characteristics, age, and wish to preserve the uterus and fertility. There is growing evidence of the main role of progesterone pathways in the pathophysiology of uterine fibroids due to the use of selective progesterone receptor modulators such as ulipristal acetate. The efficacy of long-term intermittent use of UPA was recently demonstrated by randomised controlled studies. There is great demand for alternatives to surgical intervention, especially in women seeking to preserve their fertility. One of these alternatives is ulipristal acetate, which is proven to treat fibroid symptoms effectively. Termedia Publishing House 2017-12-30 2017-12 /pmc/articles/PMC5824685/ /pubmed/29483856 http://dx.doi.org/10.5114/pm.2017.72792 Text en Copyright © 2017 Termedia Sp. z o. o http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Review Paper
Piecak, Karolina
Milart, Paweł
Woźniakowska, Ewa
Paszkowski, Tomasz
Ulipristal acetate as a treatment option for uterine fibroids
title Ulipristal acetate as a treatment option for uterine fibroids
title_full Ulipristal acetate as a treatment option for uterine fibroids
title_fullStr Ulipristal acetate as a treatment option for uterine fibroids
title_full_unstemmed Ulipristal acetate as a treatment option for uterine fibroids
title_short Ulipristal acetate as a treatment option for uterine fibroids
title_sort ulipristal acetate as a treatment option for uterine fibroids
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824685/
https://www.ncbi.nlm.nih.gov/pubmed/29483856
http://dx.doi.org/10.5114/pm.2017.72792
work_keys_str_mv AT piecakkarolina ulipristalacetateasatreatmentoptionforuterinefibroids
AT milartpaweł ulipristalacetateasatreatmentoptionforuterinefibroids
AT wozniakowskaewa ulipristalacetateasatreatmentoptionforuterinefibroids
AT paszkowskitomasz ulipristalacetateasatreatmentoptionforuterinefibroids